Biodegradable and Bioresorbable Medical Devices: Market Outlook
What Are Bioresorbable Devices?
Bioresorbable (also called biodegradable or absorbable) medical devices are made from materials that break down in the body over a defined time period through hydrolysis, enzymatic degradation, or both — producing metabolites that are safely excreted or incorporated into normal metabolic pathways. The breakdown timeline ranges from weeks (some sutures) to years (certain orthopaedic fixation screws).
Key material families:
- Poly(lactic acid) — PLA and PLLA: Most widely used bioresorbable polymer; degradation 6 months–4 years depending on crystallinity. Applications: sutures, bone screws, interference screws, guided tissue regeneration membranes
- Poly(glycolic acid) — PGA: Faster degrading (2–4 weeks); used in sutures, wound closure, and scaffolds
- PLGA (PLA-PGA copolymer): Tunable degradation rate; most versatile bioresorbable polymer; drug delivery, scaffolds, wound care
- Poly(caprolactone) — PCL: Very slow degrading (2–4 years); bone scaffolds, slow drug delivery
- Natural polymers: Collagen, hyaluronic acid, chitosan — used in wound care, cartilage scaffolds, and dermal fillers
- Bioresorbable metals: Magnesium alloys (bone screws, cardiovascular stents) — an emerging category with high growth potential
Market Size and Fastest-Growing Applications
| Application Segment | Market Size (2025) | CAGR (2025–2030) | Key Products |
|---|---|---|---|
| Bioresorbable sutures | USD ~1.8 billion | ~8.5% | Vicryl (PGA), PDS (PDS-II), Monocryl — competitive market |
| Orthopaedic fixation | USD ~1.1 billion | ~14.2% | Bioresorbable bone screws, interference screws, anchors |
| Cardiovascular — bioresorbable scaffolds | USD ~420 million | ~22.8% | Bioresorbable vascular scaffolds (BVS) — post-Absorb NXT generation |
| Guided tissue/bone regeneration | USD ~680 million | ~16.7% | Bioresorbable membranes for dental/orthopaedic bone regeneration |
| Wound care / skin substitutes | USD ~780 million | ~12.4% | Collagen wound matrices, PLGA wound dressings |
Regulatory Classification — Where the Complexity Lies
Bioresorbable devices face complex EU MDR classification because their degradation products interact with the body — creating biological risk considerations beyond those of non-resorbable materials:
- EU MDR Rule 18: Devices made from non-viable tissues or cells of human or animal origin, or their derivatives, are Class III — this applies to animal-derived collagen wound dressings and other biologically-derived bioresorbable materials
- Rule 8 (implantable devices): Bioresorbable implants (bone screws, interference screws) are Class IIb or Class III depending on invasiveness and contact duration
- ISO 10993 biocompatibility: Bioresorbable devices require extensive biocompatibility assessment covering not just the parent material but all expected degradation products — this is the most technically demanding aspect of bioresorbable device Technical Files
- Degradation testing: In vitro and in vivo degradation characterisation — demonstrating that the device degrades at the claimed rate and that degradation products are safely metabolised
- Mechanical performance during degradation: For structural bioresorbable devices (bone screws, scaffolds), demonstrating that mechanical performance is maintained until the healing biology no longer requires it
Opportunities for Turkish Manufacturers
- Bioresorbable suture manufacturing: Türkiye has established medical textile and polymer manufacturing capability. PGA/PLGA suture manufacturing is technically accessible and the global market is large and growing — Turkish suture manufacturers could develop bioresorbable suture lines as a value-added extension of existing suture portfolios
- Guided bone regeneration membranes: PLGA and collagen-based GBR membranes for dental and orthopaedic bone regeneration are a high-value, lower-volume segment accessible to Turkish biomaterial manufacturers
- Bioresorbable wound dressings: Türkiye's medical textile capability can extend to collagen wound matrix and PLGA wound dressing development — attractive EU MDR Class IIb/III premium products with 12.4% market CAGR
- TÜBİTAK-funded biomaterial R&D: Turkish university polymer chemistry departments (METU, ITU, Hacettepe) have bioresorbable polymer research capability — Turkish manufacturers can partner for co-development projects eligible for TÜBİTAK TEYDEB funding
The Magnesium Bioresorbable Revolution
Magnesium alloy bioresorbable devices represent the next major category — magnesium corrodes safely in the body, providing structural support for bone fracture healing before degrading over 6–24 months. This eliminates the need for removal surgery that non-resorbable titanium fixation often requires.
MAGNEZIX magnesium screws (Syntellix, Germany) are an early commercial example. The market is growing rapidly as clinical evidence accumulates and manufacturing costs decrease. Turkish manufacturers with metal forming, machining, and orthopaedic device manufacturing capability should monitor the magnesium bioresorbable space as a significant product development opportunity for 2027–2030.